IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mariner LLC

Mariner LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,072 shares of the medical research company's stock after selling 3,736 shares during the quarter. Mariner LLC's holdings in IQVIA were worth $2,765,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of IQV. World Investment Advisors LLC acquired a new position in IQVIA in the 3rd quarter worth approximately $14,633,000. Arvest Bank Trust Division acquired a new position in IQVIA in the 3rd quarter worth approximately $21,079,000. Wilmington Savings Fund Society FSB acquired a new position in IQVIA in the 3rd quarter worth approximately $2,310,000. Tidal Investments LLC increased its holdings in shares of IQVIA by 9.3% during the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock valued at $1,417,000 after purchasing an additional 509 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of IQVIA by 1.2% during the 3rd quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock valued at $117,031,000 after purchasing an additional 6,011 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IQV. Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the company from $260.00 to $160.00 in a research note on Friday. Truist Financial dropped their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Finally, Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $237.62.

IQVIA Trading Down 0.1 %

Shares of IQV stock traded down $0.12 during trading hours on Monday, hitting $150.16. The company had a trading volume of 1,457,526 shares, compared to its average volume of 1,423,573. The company's fifty day moving average is $170.67 and its 200 day moving average is $193.00. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The stock has a market capitalization of $26.48 billion, a PE ratio of 20.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.